FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $92 from $86 based on our discounted cash flow analysis. We widen our 2026 loss per share forecast to -$2.62 from -$2.42 and our 2027 loss per share estimate to -$0.66 from -$0.35. IONS demonstrated significant positive momentum, reporting a very strong Q1 and significantly beating revenue and LPS estimates. Total Q1 revenue surged to $246M (+87% Y/Y) driven by robust operational execution and accelerating demand for Ionis' key commercial products. TRYNGOLZA (Olezarsen) sales rose by a record 350% Y/Y and DAWNZERA sales increased by 125% Q/Q in Q1. The upcoming launch of Olezarsen in severe hypertriglyceridemia (sHTG) indication targets a large addressable market of over 3 million patients and positions the treatment to be Ionis' first wholly-owned blockbuster medicine, in our view. We think the pipeline progress and successful operational execution position Ionis well for substantial near-term growth, reinforcing its evolution into a fully integrated commercial biotech company.

Related Articles

Australia

Alignment Healthcare Swings to Q1 Profit, Revenue Rises; Shares Fall After Hours

Alignment Healthcare (ALHC) reported Q1 earnings late Thursday of $0.05 per diluted share, compared with the loss of $0.05 a year earlier.Analysts polled by FactSet expected earnings of $0.01.Revenue in the three months ended March 31 rose to $1.24 billion from $926.9 million a year ago.Analysts surveyed by FactSet expected $1.22 billion.The company expects revenue of $1.3 billion to $1.32 billion in Q2 and $5.16 billion to $5.21 billion in the full year.Analysts project $1.31 billion in Q2 and $5.17 billion in 2026.Alignment Healthcare shares fell 10% in after-hours trading.

$ALHC
Research

Research Alert: Columbia Sportswear Company Beats Estimates; Raises Full-year Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:COLM posted Q1 2026 EPS of $0.65 vs. $0.75 prior year, $0.30 above consensus on flat net sales of $779M, $21M above estimates. International diversification proved valuable with EMEA surging 35% and LAAP growing 5%, offsetting a 10% U.S. decline, while gross margin contracted 20 bps to 50.7% primarily from a 310-bp incremental tariff impact. We believe the international growth strategy is effectively insulating the company from U.S. tariff headwinds and positioning it for sustained global expansion. Management raised full-year EPS guidance to $3.55-$4.00 from prior $3.20-$3.65 and operating margin guidance to 6.7%-7.5% reflecting better tariff conditions. The company maintains its fortress balance sheet with $535.4M cash and no debt while executing a $150M share repurchase program. We are impressed with international performance driving growth and expect continued momentum from the ACCELERATE Growth Strategy targeting younger consumers, with shares trading at 17x forward EPS guidance.

$COLM
Mining & Metals

Fairfax India Holdings Corp Announcing FY25 Net Earnings of US$410.5M or $3.05 Net Earnings Per Diluted Share

$FIH-U.TO